Claims for Patent: 6,864,257
✉ Email this page to a colleague
Summary for Patent: 6,864,257
| Title: | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
| Abstract: | Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-d ihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics. |
| Inventor(s): | Cotrel; Claude (Paris, FR), Roussel; Gerard (Soisy sur Seine, FR) |
| Assignee: | Sepracor Inc. (Marlborough, MA) |
| Application Number: | 10/200,510 |
| Patent Claims: |
1. A method of inducing an effect selected from the group consisting of a hypnotic effect, a sedative effect and a tranquilizing effect, in a human in need of said induction,
comprising administering to the human an effective quantity of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-d ihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, in the form of its dextrorotatory
isomer and essentially free of its levorotatory isomer.
2. The method according to claim 1, wherein said administering step comprises administering a pharmaceutical composition comprising an effective amount of said 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)-carbonyloxy]-7-oxo-6,7- dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, in the form of its dextrorotatory isomer and essentially free of its levorotatory isomer, and a pharmaceutically acceptable carrier. 3. The method according to claim 1, wherein the pharmaceutically acceptable salt is a salt of a mineral acid, or a substituted derivative thereof, selected from the group consisting of hydrochlorides, sulfates, nitrates, and phosphates. 4. The method according to claim 1, wherein the pharmaceutically acceptable salt is a salt of an organic acid, or a substituted derivative thereof, selected from the group consisting of acetates, propionates, succinates, benzoates, fumarates, tartrates, theophyllineacetates, salicylates, and phenolphthalinates. 5. The method according to claim 1, wherein the effective quantity is from about 2.5 mg to about 15 mg per day. 6. The method according to claim 2,wherein the pharmaceutically acceptable carrier comprises a diluent. 7. The method according to claim 2 wherein the composition is administered orally, rectally or parenterally. |
